- Home
- MBIO vs SLXN Comparison
MBIO vs SLXN Comparison
Compare MBIO & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- SLXN
- Stock Information
- Founded
- MBIO 2015
- SLXN 2008
- Country
- MBIO United States
- SLXN Israel
- Employees
- MBIO N/A
- SLXN N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- MBIO Health Care
- SLXN
- Exchange
- MBIO Nasdaq
- SLXN NYSE
- Market Cap
- MBIO 7.3M
- SLXN 6.9M
- IPO Year
- MBIO N/A
- SLXN N/A
- Fundamental
- Price
- MBIO $1.24
- SLXN $0.95
- Analyst Decision
- MBIO
- SLXN Strong Buy
- Analyst Count
- MBIO 0
- SLXN 1
- Target Price
- MBIO N/A
- SLXN $5.00
- AVG Volume (30 Days)
- MBIO 102.5K
- SLXN 1.2M
- Earning Date
- MBIO 05-14-2025
- SLXN 05-13-2025
- Dividend Yield
- MBIO N/A
- SLXN N/A
- EPS Growth
- MBIO N/A
- SLXN N/A
- EPS
- MBIO N/A
- SLXN N/A
- Revenue
- MBIO N/A
- SLXN N/A
- Revenue This Year
- MBIO N/A
- SLXN N/A
- Revenue Next Year
- MBIO N/A
- SLXN N/A
- P/E Ratio
- MBIO N/A
- SLXN N/A
- Revenue Growth
- MBIO N/A
- SLXN N/A
- 52 Week Low
- MBIO $1.01
- SLXN $0.58
- 52 Week High
- MBIO $65.00
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- MBIO 47.58
- SLXN N/A
- Support Level
- MBIO $1.25
- SLXN N/A
- Resistance Level
- MBIO $1.34
- SLXN N/A
- Average True Range (ATR)
- MBIO 0.07
- SLXN 0.00
- MACD
- MBIO 0.01
- SLXN 0.00
- Stochastic Oscillator
- MBIO 61.54
- SLXN 0.00
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.